Myasthenia gravis: New therapeutic approaches based on pathophysiology

被引：10
作者：
Lewis, Richard A. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2013年 / 333卷 / 1-2期
关键词：
Myasthenia gravis; Antibodies; Therapy; Neuromuscular Junction; Lymphocytes; Thymus; QUALITY STANDARDS SUBCOMMITTEE; CELL-ACTIVATING FACTOR; ACETYLCHOLINE-RECEPTOR; AMERICAN-ACADEMY; T-CELLS; ANTIBODIES; MUSK; CYCLOPHOSPHAMIDE; AUTOANTIBODIES; AZATHIOPRINE;
D O I：
10.1016/j.jns.2013.06.018
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Over the past 40 years Dr. Robert Lisak has made important contributions to our understanding of the pathophysiology and therapy of myasthenia gravis. This review will touch upon some of his work as it discusses current therapies and the potential for new treatments based on the evolving knowledge of the underlying basis of the disease. The recognition of different immune mechanisms that can cause the phenotype that we acknowledge as myasthenia gravis coincides with the introduction of monoclonal antibodies and other new therapies that can target specific aspects of the disease. This has raised our hopes for treatments that will have less side effects and be more effective. In some cases these hopes have been realized. In other instances, the situation remains a "work in progress". Dr. Lisak's work and teachings remain cogent to our modern approach to this classic immunologic disease. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码：93 / 98
页数：6
相关论文
共 46 条
[1]   THYMUS IN MYASTHENIA-GRAVIS - EVIDENCE FOR ALTERED CELL-POPULATIONS [J].
ABDOU, NI ;
LISAK, RP ;
ZWEIMAN, B ;
ABRAHAMSOHN, I ;
PENN, AS .
NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (24) :1271-1275
[2]   Comparison of IVIg and PLEX in patients with myasthenia gravis [J].
Barth, D. ;
Nouri, M. Nabavi ;
Ng, E. ;
Nwe, P. ;
Bril, V. .
NEUROLOGY, 2011, 76 (23) :2017-2023
[3]   Evidence report: The medical treatment of ocular myasthenia (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology [J].
Benatar, Michael ;
Kaminski, Henry J. .
NEUROLOGY, 2007, 68 (24) :2144-2149
[4]   Treatment of ocular symptoms in myasthenia gravis [J].
Bhanushali, Minal J. ;
Wuu, Joanne ;
Benatar, Michael .
NEUROLOGY, 2008, 71 (17) :1335-1341
[5]   THE THYMUS IN MYASTHENIA GRAVIS: SITE OF "INNATE AUTOIMMUNITY"? [J].
Cavalcante, Paola ;
Le Panse, Rozen ;
Berrih-Aknin, Sonia ;
Maggi, Lorenzo ;
Antozzi, Carlo ;
Baggi, Fulvio ;
Bernasconi, Pia ;
Mantegazza, Renato .
MUSCLE & NERVE, 2011, 44 (04) :467-484
[6]   Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future [J].
Dalakas, Marinos C. .
MYASTHENIA GRAVIS AND RELATED DISORDERS I, 2012, 1274 :1-8
[7]   PLASMAPHERESIS AND IMMUNOSUPPRESSIVE DRUG-THERAPY IN MYASTHENIA-GRAVIS [J].
DAU, PC ;
LINDSTROM, JM ;
CASSEL, CK ;
DENYS, EH ;
SHEV, EE ;
SPITLER, LE .
NEW ENGLAND JOURNAL OF MEDICINE, 1977, 297 (21) :1134-1140
[8]   Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis [J].
De Feo, LG ;
Schottlender, J ;
Martelli, NA ;
Molfino, NA .
MUSCLE & NERVE, 2002, 26 (01) :31-36
[9]   Safety of plasma exchange therapy in patients with myasthenia gravis [J].
Ebadi, Hamid ;
Barth, David ;
Bril, Vera .
MUSCLE & NERVE, 2013, 47 (04) :510-514
[10]   Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis [J].
Evoli, A ;
Tonali, PA ;
Padua, L ;
Lo Monaco, M ;
Scuderi, F ;
Batocchi, AP ;
Marino, M ;
Bartoccioni, E .
BRAIN, 2003, 126 :2304-2311
12345